Genetic Prevention for Tumor Diseases

Looks for germline predispositions associated with hereditary tumors of the breast, ovary, digestive tract, endocrine organs, skin, nervous system, kidney, and other organs.

Discuss this test →Use clinical selector ↗

STARTING MATERIAL

1–2 ml EDTA blood or 1–2 µg genomic DNA. Alternative material must be confirmed before collection or shipment.

METHOD / ANALYTICAL SCOPE

Targeted next-generation sequencing of the complete coding sequence and relevant splice regions of the selected genes; this is not a hotspot-only screen.

MEDICAL REPORT

Clinically classified findings, an explanation of the inherited risk, and recommendations for medical follow-up or preventive discussion.

TURNAROUND

Confirmed after module selection and sample review.

CLINICAL VALUE

Where this test is strongest

✓54-gene comprehensive module

✓Full-gene analysis rather than common variants only

✓Separate breast and prostate options

✓Can support risk-adapted surveillance discussion

LIMITATIONS

What must remain visible

!A predisposition is not a diagnosis and does not predict if or when disease will occur.

!A negative result does not remove all inherited or non-genetic risk; selection and interpretation require medical context.

GENE & ANALYTICAL SCOPE

54 published genes

Choose the broad 54-gene module or a narrower indication-specific option.

Tumor diseasesPRV01 · 54 published genes

Comprehensive hereditary tumor predisposition module (54 genes).

APCATMAXIN2BAP1BARD1BMPR1ABRCA1BRCA2BRIP1CDC73CDH1CDKN2ACHEK2DICER1EPCAMFHFLCNKITMAXMEN1METMLH1MSH2MSH6MUTYHNBNNF1NF2PALB2PDGFRAPMS2POLD1POLEPTCH1PTENRAD51CRAD51DRB1RETSDHASDHAF2SDHBSDHCSDHDSMAD4SMARCA4SMARCB1STK11TMEM127TP53TSC1TSC2VHLWT1

Breast cancerPRV10 · 18 published genes

Breast cancer predisposition option (18 genes).

ATMBARD1BRCA1BRCA2BRIP1CDH1CHEK2EPCAMMLH1MSH2MSH6PALB2PMS2PTENRAD51CRAD51DSTK11TP53

Prostate cancerPRV11 · 10 published genes

Prostate cancer predisposition option (10 genes).

ATMBRCA1BRCA2CHEK2MLH1MSH2MSH6NBNPMS2TP53

Search another gene across the portfolio →

BEFORE ORDERING

Confirm the current laboratory specification.

The official case review and quotation confirm eligibility, accepted material, validated coverage and variant classes, consent, turnaround, price, and report pathway.

Prepare case enquiry →